carbamazepine has been researched along with Anxiety Neuroses in 22 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to examine the possibility that patients with panic disorder are especially vulnerable to alprazolam withdrawal, as well as to evaluate the efficacy of carbamazepine as adjunctive treatment during alprazolam discontinuation." | 9.07 | Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. ( Colin, V; Klein, E; Lenox, RH; Stolk, J, 1994) |
| "This analysis is a retrospective chart review evaluating the safety of carbamazepine (CBZ) extended-release capsules (CBZ-ERC) (Shire, Wayne, PA, USA) when used in combination with other agents as part of a polypharmacy regimen in the treatment of patients with bipolar disorder." | 7.73 | Safety of carbamazepine extended-release capsules in bipolar disorder polypharmacy. ( Ginsberg, LD, 2006) |
| "This study was designed to examine the possibility that patients with panic disorder are especially vulnerable to alprazolam withdrawal, as well as to evaluate the efficacy of carbamazepine as adjunctive treatment during alprazolam discontinuation." | 5.07 | Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. ( Colin, V; Klein, E; Lenox, RH; Stolk, J, 1994) |
| "This analysis is a retrospective chart review evaluating the safety of carbamazepine (CBZ) extended-release capsules (CBZ-ERC) (Shire, Wayne, PA, USA) when used in combination with other agents as part of a polypharmacy regimen in the treatment of patients with bipolar disorder." | 3.73 | Safety of carbamazepine extended-release capsules in bipolar disorder polypharmacy. ( Ginsberg, LD, 2006) |
| " Under the treatment with carbamazepine panic attacks improved." | 3.69 | [Panic attacks with cycloleptic course--differential diagnostic considerations in differentiating panic disorder from epileptic anxiety attacks]. ( Assion, HJ; Heinemann, F, 1996) |
| "Agents introduced for the treatment of epilepsy have also been usedsimultaneously for psychiatric indications." | 2.43 | [Anticonvulsants treatment of psychiatric disorder in elderly patients]. ( Bidzan, L, 2006) |
| "Complex partial epilepsy can be mistaken for primary child-psychiatric disorder." | 1.35 | [Panic attacks simulated by occipital lobe seizures]. ( Püst, B; Sieben, C; Stolle, M, 2009) |
| "Alprazolam treatment is effective for panic disorder, but its major disadvantages include possible dependence and withdrawal symptoms upon discontinuation." | 1.27 | Preliminary evidence for the utility of carbamazepine in alprazolam withdrawal. ( Klein, E; Post, RM; Uhde, TW, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (36.36) | 18.7374 |
| 1990's | 8 (36.36) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stolle, M | 1 |
| Sieben, C | 1 |
| Püst, B | 1 |
| Stahl, SM | 1 |
| Beresford, TP | 1 |
| Arciniegas, D | 1 |
| Clapp, L | 1 |
| Martin, B | 1 |
| Alfers, J | 1 |
| Ginsberg, LD | 1 |
| Bidzan, L | 1 |
| Kocher, R | 1 |
| Campbell, JL | 1 |
| Thomas, HM | 1 |
| Gabrielli, W | 1 |
| Liskow, BI | 1 |
| Powell, BJ | 1 |
| Kramlinger, KG | 1 |
| Phillips, KA | 1 |
| Post, RM | 3 |
| Klein, E | 2 |
| Colin, V | 1 |
| Stolk, J | 1 |
| Lenox, RH | 1 |
| Mintzer, JE | 1 |
| Brawman-Mintzer, O | 1 |
| Heinemann, F | 1 |
| Assion, HJ | 1 |
| Silva, JA | 1 |
| Tekell, JL | 1 |
| Penny, G | 1 |
| Bowden, CL | 1 |
| De la Fuente, JM | 1 |
| Mendlewicz, J | 1 |
| Springer, JA | 1 |
| Garvey, MJ | 1 |
| Varney, NR | 1 |
| Roberts, RJ | 1 |
| Marangos, PJ | 1 |
| Boulenger, JP | 1 |
| Uhde, TW | 2 |
| Tondo, L | 1 |
| Burrai, C | 1 |
| Scamonatti, L | 1 |
| Toccafondi, F | 1 |
| Poddighe, A | 1 |
| Minnai, G | 1 |
| Tundo, A | 1 |
| Floris, G | 1 |
| Stein, MB | 1 |
| Stoudemire, A | 1 |
| Ninan, PT | 1 |
| Wooten, V | 1 |
| Edlund, MJ | 1 |
| Swann, AC | 1 |
| Clothier, J | 1 |
| Lawlor, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial[NCT02235064] | 2 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Low recruitment, completion of funding cycle) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 1 |
"Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment~0 = No postpartum depression up to 12 weeks following discharge from hospital~1 = Postpartum depression up to 12 weeks following discharge from hospital" (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 4734 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 3033 |
| Placebo | 2750 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 3685 |
5 reviews available for carbamazepine and Anxiety Neuroses
| Article | Year |
|---|---|
Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA.
Topics: Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Carbamazepine; Fructose; GABA Agonists; gam | 2004 |
[Anticonvulsants treatment of psychiatric disorder in elderly patients].
Topics: Aged; Anticonvulsants; Anxiety Disorders; Bipolar Disorder; Carbamazepine; Epilepsy; Humans; Mental | 2006 |
ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Breast Feed | 2008 |
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach.
Topics: Aged; Aggression; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Buspirone; Carbamazepin | 1996 |
Basic and clinical aspects of adenosinergic neuromodulation.
Topics: Adenosine; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Arousal; Benzodia | 1985 |
4 trials available for carbamazepine and Anxiety Neuroses
| Article | Year |
|---|---|
Impact of desipramine or carbamazepine on patient retention in outpatient cocaine treatment: preliminary findings.
Topics: Ambulatory Care; Antisocial Personality Disorder; Anxiety Disorders; Carbamazepine; Cocaine; Combine | 1994 |
Rash complicating carbamazepine treatment.
Topics: Adult; Anxiety Disorders; Bipolar Disorder; Carbamazepine; Depressive Disorder; Double-Blind Method; | 1994 |
Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine.
Topics: Adult; Alprazolam; Anxiety Disorders; Carbamazepine; Double-Blind Method; Drug Administration Schedu | 1994 |
Lack of efficacy of carbamazepine in the treatment of panic disorder.
Topics: Adult; Agoraphobia; Anxiety Disorders; Carbamazepine; Clinical Trials as Topic; Fear; Female; Humans | 1988 |
13 other studies available for carbamazepine and Anxiety Neuroses
| Article | Year |
|---|---|
[Panic attacks simulated by occipital lobe seizures].
Topics: Anticonvulsants; Anxiety Disorders; Carbamazepine; Child; Combined Modality Therapy; Compulsive Beha | 2009 |
Reduction of affective lability and alcohol use following traumatic brain injury: a clinical pilot study of anti-convulsant medications.
Topics: Adult; Alcoholism; Anticonvulsants; Anxiety Disorders; Brain Injuries; Carbamazepine; Female; Humans | 2005 |
Safety of carbamazepine extended-release capsules in bipolar disorder polypharmacy.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Anxiety Disorders; Attention Deficit Disorder with Hypera | 2006 |
[Psychopharmaceuticals in chronic pain].
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Brain; Carbamazepin | 1981 |
[Panic attacks with cycloleptic course--differential diagnostic considerations in differentiating panic disorder from epileptic anxiety attacks].
Topics: Anticonvulsants; Anxiety Disorders; Carbamazepine; Diagnosis, Differential; Epilepsy, Temporal Lobe; | 1996 |
Resolution of palinopsia with carbamazepine.
Topics: Adult; Afterimage; Anxiety Disorders; Carbamazepine; Humans; Male; Psychotic Disorders | 1997 |
Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression.
Topics: Aged; Anxiety Disorders; Carbamazepine; Clomipramine; Depressive Disorder; Dose-Response Relationshi | 1992 |
Dichotic listening failure in dysphoric neuropsychiatric patients who endorse multiple seizure-like symptoms.
Topics: Adult; Anxiety Disorders; Auditory Perception; Auditory Threshold; Carbamazepine; Depressive Disorde | 1991 |
Preliminary evidence for the utility of carbamazepine in alprazolam withdrawal.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Carbamazepine; Female; H | 1986 |
Carbamazepine in panic disorder.
Topics: Adult; Agoraphobia; Anxiety Disorders; Carbamazepine; Fear; Female; Humans; Male; Middle Aged; Panic | 1989 |
Hypnogenic paroxysmal dystonia with panic attacks responsive to drug therapy.
Topics: Adult; Anxiety Disorders; Carbamazepine; Dystonia; Fear; Female; Humans; Panic; Seizures; Syndrome | 1987 |
Patients with panic attacks and abnormal EEG results.
Topics: Adult; Alprazolam; Anxiety Disorders; Brain; Carbamazepine; Electroencephalography; Fear; Female; Hu | 1987 |
Carbamazepine, alprazolam withdrawal, and panic disorder.
Topics: Alprazolam; Anxiety Disorders; Carbamazepine; Fear; Humans; Panic; Substance Withdrawal Syndrome | 1987 |